Parexel regulatory expert, Mark Birse, gives an update on BREXIT.
Clinical trials of (CAR) T-cell therapies can present unprecedented enrolment challenges. How can we encour...
Other content in this Stream
It is essential to address the payer landscape very early in development for a product administered once with a lifelong effect, such as a gene therapy. The one-time, front-loaded costs of these treat
Learn how Parexel brings the principles and energy from face-to-face investigator meetings to an interactive and engaging virtual environment.
Clinical trials of (CAR) T-cell therapies can present unprecedented enrolment challenges. How can we encourage participation in these trials? Doug Olson, one of the first CAR-T patients treated on a
Dr. Scott Gottlieb, Former Commissioner of the Food and Drug Administration speaks with Parexel’s Peyton Howell, Executive Vice President, Chief Commercial & Strategy Officer and Sy Pretorius, Executi
RWE experts Leanne Larson, Senior Vice President and Worldwide Head, Real-World Evidence and Access and Amy McKee, Vice President, Regulatory and Access dig deeper into the evolving role of RWE.
Parexel’s Paul Bridges, SVP Regulatory & Access and Lynne Ensor, Head of Global Compliance outline the benefits for drug manufacturers in participating in two new FDA pilot programs. These include API
Paul Bridges on the EU Clinical Trial Regulation (CTR)
Parexel’s Anita Nelsen, SVP, Translational Medicine and Michelle Hoiseth, Chief Data Officer, Corporate VP speak with Ashley Druckenmiller about caring with her two sons with hemophilia and the benefi
Parexel’s Leanne Larson, Corporate VP and WW Head, Real-world Evidence speaks with Deborah Collyar, cancer survivor and President of Advocates in Research about the importance of Real-world Evidence (
Sy Pretorius, EVP and Chief Medical & Scientific Officer, Parexel and Gadi Saarony, CEO, Advarra discuss how industry-leading innovations help to reduce the time and cost of development, minimize the
Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our experts leveraged Real-World Evidence and FDA/Regulatory expertise to develop and execute a Synthet
See how Parexel are bringing together regulatory and market access experts to help companies developing rare and orphan disease products. Learn more about our Regulatory & Access Consulting Group: htt
Parexel’s Rosamund Round, Director, Patient Innovation Center and Amy McKee, Vice President, Regulatory Consulting Services sit down with Monica Theis, a breast cancer survivor and two-time clinical t
James Anthony, SVP, Global Head Biotech and Graciela Rácaro, SVP, Global Head, Biotech Operations, both from Parexel, discuss how Parexel Biotech has been built to meet customer and the patient needs
An overview of Parexel’s Regulatory Consulting services.